This HTML5 document contains 30 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB09016/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB09016/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/sukl/drug/
n12http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB09016/identifier/kegg-drug/

Statements

Subject Item
n2:DB09016
rdf:type
n3:Drug
n3:description
Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline and produces similar effects to it, but with less marked side effects like sedation and interactions with adrenergic drugs.
n3:group
approved
owl:sameAs
n6:DB09016
dcterms:title
Butriptyline
adms:identifier
n8:D07601 n9:Butriptyline n10:DB09016
n3:synonym
(±)-3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)-N,N,2-trimethylpropan-1-amine
n3:toxicity
Side effects of tricyclic antidepressants include dry mouth, sour or metallic taste, constipation, retention of urine, blurred vision and changes in focusing, palpitations, and fast heart beat. Gastrointestinal disturbances (including nausea and vomiting), drowsiness, tremor, low blood pressure when standing, dizziness, sweating, weakness and fatigue, incoordination, epilepsy-like seizures, and speech difficulties may occur.
n3:salt
n3:synthesisReference
U.S. Patent 3,409,640.
n3:IUPAC-Name
n4:271B6507-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6506-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:N06AA15
n3:H-Bond-Acceptor-Count
n4:271B650D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B650E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6509-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B650B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B650A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B650C-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
35941-65-2
n3:Bioavailability
n4:271B6512-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6514-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6515-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6511-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6510-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6513-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6508-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B650F-363D-11E5-9242-09173F13E4C5